RxDoctor Payments Data

Cassandra Kaczmarek, APRN

Acute Care · Omaha, NENPI 1760140412

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,360 of the $1,855 with a category attached, or 73.3%. 10 manufacturers reported payments, led by Medtronic at 39.9% of the total. Reporting peaked in 2024 at $1,168 and has fallen 66.1% since, to $396 in 2025.

$1,855in general payments, 2019–2025

Across 31 payments — averaging $59.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$740
  • Abiomed$245
  • Abbott$217
  • Impulse Dynamics (USA) Inc.$176
  • Novartis$169
  • Amgen$135
  • plus $173 from 4 others

What the payments were for

  • Travel & lodging$49527%
  • Food & beverage$1,36073%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,855 in reported general payments places this provider in the 75th percentile of 103 acute care providers in Nebraska.

See all acute care providers in Nebraska

Medicare billing

Part B allowed, 2024
$5,237
Medicare patients
41
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$7,899

Paid to pharmacies, not to this prescriber.

Other acute care in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →